HRP20170795T1 - Derivati bipirazola kao inhibitori jak - Google Patents
Derivati bipirazola kao inhibitori jak Download PDFInfo
- Publication number
- HRP20170795T1 HRP20170795T1 HRP20170795TT HRP20170795T HRP20170795T1 HR P20170795 T1 HRP20170795 T1 HR P20170795T1 HR P20170795T T HRP20170795T T HR P20170795TT HR P20170795 T HRP20170795 T HR P20170795T HR P20170795 T1 HRP20170795 T1 HR P20170795T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- bipyrazol
- cyanomethyl
- Prior art date
Links
- YGAILVDTGIMZAB-UHFFFAOYSA-N 3-pyrazol-3-ylidenepyrazole Chemical class N1=NC=CC1=C1N=NC=C1 YGAILVDTGIMZAB-UHFFFAOYSA-N 0.000 title 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 91
- 150000003839 salts Chemical class 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 15
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 8
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 206010028537 myelofibrosis Diseases 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 6
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 6
- 208000003476 primary myelofibrosis Diseases 0.000 claims 6
- -1 2,2,2-trifluoro-1-methylethyl Chemical group 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000006601 (C1-C3) alkylcarbamyl group Chemical group 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- MSGYSFWCPOBHEV-AWEZNQCLSA-N 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1h-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-n-[(2s)-1,1,1-trifluoropropan-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)N[C@@H](C)C(F)(F)F)=CC(F)=C1N1CC(CC#N)(N2N=CC(=C2)C2=C(NN=C2C)C)C1 MSGYSFWCPOBHEV-AWEZNQCLSA-N 0.000 claims 4
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 4
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 4
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 3
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 3
- 208000037244 polycythemia vera Diseases 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims 2
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 2
- 206010033661 Pancytopenia Diseases 0.000 claims 2
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 claims 2
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 208000024389 cytopenia Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims 1
- PKGWUYXTDWCQPT-ZDUSSCGKSA-N 4-[3-(cyanomethyl)-3-[3-(hydroxymethyl)-4-(5-methyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide Chemical compound C[C@H](NC(=O)c1cc(F)c(cc1F)N1CC(CC#N)(C1)n1cc(c(CO)n1)-c1c[nH]nc1C)C(F)(F)F PKGWUYXTDWCQPT-ZDUSSCGKSA-N 0.000 claims 1
- YBWASPQEFFRUHU-LBPRGKRZSA-N 4-[3-(cyanomethyl)-3-[4-(1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide Chemical compound C[C@H](NC(=O)c1cc(F)c(cc1F)N1CC(CC#N)(C1)n1cc(cn1)-c1cn[nH]c1)C(F)(F)F YBWASPQEFFRUHU-LBPRGKRZSA-N 0.000 claims 1
- PEDUBHMYSRBSPA-ZDUSSCGKSA-N 4-[3-(cyanomethyl)-3-[4-(5-methyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide Chemical compound C[C@H](NC(=O)c1cc(F)c(cc1F)N1CC(CC#N)(C1)n1cc(cn1)-c1c[nH]nc1C)C(F)(F)F PEDUBHMYSRBSPA-ZDUSSCGKSA-N 0.000 claims 1
- IADHQAYOJSDLQB-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-(5-methyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)c1ccc(cc1)N1CC(CC#N)(C1)n1cc(cn1)-c1c[nH]nc1C IADHQAYOJSDLQB-UHFFFAOYSA-N 0.000 claims 1
- QONJPRQDXVLSFV-LBPRGKRZSA-N 4-[3-(cyanomethyl)-3-[4-[5-(hydroxymethyl)-1H-pyrazol-4-yl]pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide Chemical compound C[C@H](NC(=O)c1cc(F)c(cc1F)N1CC(CC#N)(C1)n1cc(cn1)-c1c[nH]nc1CO)C(F)(F)F QONJPRQDXVLSFV-LBPRGKRZSA-N 0.000 claims 1
- WDEZBQCRCIAJPW-UHFFFAOYSA-N 5-[3-(cyanomethyl)-3-[3-methyl-4-(1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-propan-2-ylpyrazine-2-carboxamide Chemical compound CC(C)NC(=O)c1cnc(cn1)N1CC(CC#N)(C1)n1cc(c(C)n1)-c1cn[nH]c1 WDEZBQCRCIAJPW-UHFFFAOYSA-N 0.000 claims 1
- UVNZXZQWOUVYIS-UHFFFAOYSA-N 5-[3-(cyanomethyl)-3-[3-methyl-4-(5-methyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-propan-2-ylpyrazine-2-carboxamide Chemical compound CC(C)NC(=O)c1cnc(cn1)N1CC(CC#N)(C1)n1cc(c(C)n1)-c1c[nH]nc1C UVNZXZQWOUVYIS-UHFFFAOYSA-N 0.000 claims 1
- IGEAGUKQINLFNW-AWEZNQCLSA-N 5-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazine-2-carboxamide Chemical compound C[C@H](NC(=O)c1cnc(cn1)N1CC(CC#N)(C1)n1cc(cn1)-c1c(C)n[nH]c1C)C(F)(F)F IGEAGUKQINLFNW-AWEZNQCLSA-N 0.000 claims 1
- JFFRGYYXQJTLOG-UHFFFAOYSA-N 5-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-propan-2-ylpyrazine-2-carboxamide Chemical compound CC(C)NC(=O)c1cnc(cn1)N1CC(CC#N)(C1)n1cc(cn1)-c1c(C)n[nH]c1C JFFRGYYXQJTLOG-UHFFFAOYSA-N 0.000 claims 1
- WSFLFFVFSPLTTE-ZDUSSCGKSA-N 5-[3-(cyanomethyl)-3-[4-(5-ethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazine-2-carboxamide Chemical compound CCc1n[nH]cc1-c1cnn(c1)C1(CC#N)CN(C1)c1cnc(cn1)C(=O)N[C@@H](C)C(F)(F)F WSFLFFVFSPLTTE-ZDUSSCGKSA-N 0.000 claims 1
- KJAVZRGMWQGUNS-ZDUSSCGKSA-N 5-[3-(cyanomethyl)-3-[4-(5-methyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazine-2-carboxamide Chemical compound C[C@H](NC(=O)c1cnc(cn1)N1CC(CC#N)(C1)n1cc(cn1)-c1c[nH]nc1C)C(F)(F)F KJAVZRGMWQGUNS-ZDUSSCGKSA-N 0.000 claims 1
- ZNDIFOVCUNVGNF-UHFFFAOYSA-N 5-[3-(cyanomethyl)-3-[4-(5-methyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-propan-2-ylpyrazine-2-carboxamide Chemical compound CC(C)NC(=O)c1cnc(cn1)N1CC(CC#N)(C1)n1cc(cn1)-c1c[nH]nc1C ZNDIFOVCUNVGNF-UHFFFAOYSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000009527 Refractory anemia Diseases 0.000 claims 1
- 208000034442 Refractory anemia with excess blasts type 1 Diseases 0.000 claims 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 206010070835 Skin sensitisation Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000012846 myelodysplastic syndrome with excess blasts-1 Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 231100000370 skin sensitisation Toxicity 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Claims (27)
1. Spoj, koji ima Formulu I:
[image]
ili njegova farmaceutski prihvatljiva sol;
gdje:
Cy1 je fenil, piridil, pirimidinil, pirazinil, ili piridazinil, od kojih je svaki proizvoljno supstituiran s 1, 2, 3, ili 4 skupine, koje se neovisno biraju između R3, R4, R5 i R6;
Y je N ili CH;
R1 je C1-6 alkil, C1-6 haloalkil, C3-7 cikloalkil, C3-7 cikloalkil-C1-3 alkil, 4-člani do 7-člani heterocikloalkil, 4-člani do 7-člani heterocikloalkil-C1-3 alkil, fenil, fenil-C1-3 alkil, 5-člani do 7-člani heteroaril ili 5-člani do 6-člani heteroaril-C1-3 alkil, od kojih je svaki proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se neovisno biraju između fluoro, kloro, C1-3 alkil, -OH, -O(C1-3 alkil), -CN, -CF3, -CHF2, -CH2F,
-NH2, -NH(C1-3 alkil), -N(C1-3 alkil)2, -C(=O)N(C1-3 alkil)2, -C(=O)NH(C1-3 alkil),
-C(=O)NH2, -C(=O)O(C1-3 alkil), -S(=O)2(C1-3 alkil), -S(=O)2(C3-6 cikloalkil),
-C(=O)(C3-6 cikloalkil) i -C(=O)(C1-3 alkil);
R2 je H ili C1-3 alkil; pri čemu je navedeni C1-3 alkil proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se neovisno biraju između fluoro, kloro, -OH, -O(C1-3 alkil), -CN, -CF3, -CHF2, -CH2F, NH2, -NH(C1-3 alkil) i -N(C1-3 alkil)2; ili
R1 i R2, zajedno s atomom dušika za koji su vezani, tvore 4-, 5- ili 6-člani heterocikloalkilni prsten, koji je proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se neovisno biraju između F, Cl, -OH, -O(C1-3 alkil), -CN, C1-3 alkil, C1-3 haloalkil, -NH2, -NH(C1-3 alkil), -N(C1-3 alkil)2, -CH2CN i -CH2OH;
R3 je H, F, Cl, -CN, C1-3 alkil, C1-3 fluoroalkil, -O(C1-3 alkil), ili -O(C1-3 fluoroalkil);
R4 je H, F, Cl, -CN, C1-3 alkil, C1-3 fluoroalkil, -O(C1-3 alkil), ili -OC(C1-3 fluoroalkil);
R5 je H, F, Cl, -CN, C1-3 alkil, C1-3 fluoroalkil, -O(C1-3 alkil), ili -OC(C1-3 fluoroalkil);
R6 je H, F, Cl, -CN, C1-3 alkil, C1-3 fluoroalkil, -O(C1-3 alkil), ili -OC(C1-3 fluoroalkil);
R7 je H, F, Cl, C1-3 alkil, C1-3 haloalkil, -NR17R17a, -NHC(=O)R17b,
-C(=O)NR17aR17b, -NHS(=O)2R17b ili S(=O)2NR17aR17b, pri čemu je navedeni C1-3 alkil proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se biraju između F, Cl, -CN, -CF3,-CHF2, -CH2F, -NH2, -NH(CH3), -N(CH3)2, OH, -OCH3, -OCF3,
-OCHF2, i -OCH2F;
R8 je H, F, Cl, C1-3 alkil, ili C1-3 haloalkil;
R9 je H, F, Cl, C1-3 alkil, C1-3 haloalkil, ciklopropil, -CN, -NH2, -NH(C1-3 alkil), ili
-N(C1-3 alkil)2, pri čemu je navedeni C1-3 alkil proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se biraju između F, kloro, -CN, -CF3, -CHF2, -CH2F, -NH2 i OH;
R10 je H, F, Cl, C1-3 alkil, C1-3 haloalkil, ciklopropil, -CN, -NH2, -NH(C1-3 alkil), ili -N(C1-3 alkil)2, pri čemu je navedeni C1-3 alkil proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se biraju između F, kloro, -CN, -CF3, -CHF2, -CH2F, -NH2 i OH;
R17 je C1-6 alkil, fenil ili 5-člani do 6-člani heteroaril, od kojih je svaki proizvoljno supstituiran s 1, 2, 3 ili 4 supstituenta koji se neovisno biraju od R27;
R17a je H ili C1-3 alkil;
R17b je C1-3 alkil, proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se biraju od F, kloro, -CN, -CF3, -CHF2, -CH2F, -NH2, -NH(CH3), -N(CH3)2, OH,
-OCH3 i -OCF3, -OCHF2 i -OCH2F; i
svaki R27 se neovisno bira između halo, -OH, NO2, -CN, C1-3 alkil, C2-3 alkenil, C2-3 alkinil, C1-3 haloalkil, cijano-C1-3 alkil, HO-C1-3 alkil, CF3-C1-3 hidroksialkil, C1-3 alkoksi-C1-3 alkil, C3-7 cikloalkil, C1-3 alkoksi, C1-3 haloalkoksi, H2N-, (C1-3 alkil)NH-, (C1-3 alkil)2N-, HS-, C1-3 alkil-S-, C1-3 alkil-S(=O)-, C1-3 alkil-S(=O)2-, karbamil, C1-3 alkilkarbamil, di(C1-3 alkil)karbamil, karboksi, C1-3 alkil-C(=O)-, C1-4 alkoksi-C(=O)-, C1-3 alkil-C(=O)O-, C1-3 alkil-C(=O)NH-, C1-3 alkil-S(=O)2NH-, H2N-SO2-, C1-3 alkil-NH-S(=O)2-, (C1-3 alkil)2N-S(=O)2-, H2N-S(=O)2NH-, C1-3 alkil-NHS(=O)2NH-, (C1-3 alkil)2N-S(=O)2NH-, H2N-C(=O)NH-, C1-3 alkil-NHC(=O)NH- i (C1-3 alkil)2N-C(=O)NH-.
2. Spoj prema zahtjevu 1, koji ima Formulu Ia:
[image]
ili njegova farmaceutski prihvatljiva sol;
gdje:
X je N ili CR4; i
W je N ili CR6.
3. Spoj prema zahtjevu 1, koji ima Formulu Ia:
[image]
ili njegova farmaceutski prihvatljiva sol;
gdje:
X je N ili CR4;
W je N ili CR6;
Y je N ili CH;
R1 je C1-6 alkil, C1-6 haloalkil, C3-6 cikloalkil, C3-6 cikloalkil-C1-3 alkil, 4-člani do 6-člani heterocikloalkil, ili 4-člani do 6-člani heterocikloalkil-C1-3 alkil, od kojih je svaki proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se neovisno biraju između fluoro, kloro, C1-3 alkil, -OH, -O(C1-3 alkil), -CN, -CF3, -CHF2, -CH2F, -NH2,
-NH(C1-3 alkil), -N(C1-3 alkil)2, -C(=O)N(C1-3 alkil)2, -C(=O)NH(C1-3 alkil),
-C(=O)NH2, -C(=O)O(C1-3 alkil), -S(=O)2(C1-3 alkil), -S(=O)2(C3-6 cikloalkil),
-C(=O)(C3-6 cikloalkil) i -C(=O)(C1-3 alkil);
R2 je H ili C1-3 alkil; pri čemu je navedeni C1-3 alkil proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se neovisno biraju između fluoro, kloro, -OH, -O(C1-3 alkil), -CN, -CF3, -CHF2, -CH2F, NH2, -NH(C1-3 alkil) i -N(C1-3 alkil)2; ili
R1 i R2, zajedno s atomom dušika za koji su vezani, tvore 4-, 5- ili 6-člani heterocikloalkilni prsten, koji je proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se neovisno biraju između fluoro, -OH, -O(C1-3 alkil), -CN, C1-3 alkil, C1-3 haloalkil, -NH2, -NH(C1-3 alkil), -N(C1-3 alkil)2 i -CH2CN;
R3 je H, F, Cl, -CN, C1-3 alkil, -OCF3, -CF3, ili -O(C1-3 alkil);
R4 je H, F, Cl, -CN, C1-3 alkil, ili -O(C1-3 alkil);
R5 je H, F, Cl, -CN, C1-3 alkil, ili -O(C1-3 alkil);
R6 je H, F, Cl, -CN, ili C1-3 alkil;
R7 je H, F, Cl, C1-3 alkil, C1-3 haloalkil, -NR17R17a, -NHC(=O)R17b,
-C(=O)NR17aR17b, -NHS(=O)2R17b ili -S(=O)2NR17aR17b, pri čemu je navedeni C1-3 alkil proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se biraju između F, Cl, -CN, -CF3,-CHF2, -CH2F, -NH2 i OH;
R8 je H, F, Cl, C1-3 alkil, ili C1-3 haloalkil;
R9 je H, F, Cl, C1-3 alkil, C1-3 haloalkil, ciklopropil, -CN, -NH2, -NH(C1-3 alkil), ili
-N(C1-3 alkil)2, pri čemu je navedeni C1-3 alkil proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se biraju između F, kloro, -CN, -CF3, -CHF2, -CH2F, -NH2 i OH;
R10 je H, F, Cl, C1-3 alkil, C1-3 haloalkil, ciklopropil, -CN, -NH2, -NH(C1-3 alkil), ili -N(C1-3 alkil)2, pri čemu je navedeni C1-3 alkil proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se biraju između F, kloro, -CN, -CF3, -CHF2, -CH2F, -NH2 i OH;
R17 je C1-6 alkil, fenil ili 5-člani do 6-člani heteroaril, od kojih je svaki proizvoljno supstituiran s 1, 2, 3 ili 4 supstituenta koji se neovisno biraju od R27;
R17a je H ili C1-3 alkil;
R17b je C1-3 alkil proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se biraju između F, kloro, -CN, -CF3, -CHF2, -CH2F, -NH2 i OH, i
svaki R27 se neovisno bira između halo, -OH, NO2, -CN, C1-3 alkil, C2-3 alkenil, C2-3 alkinil, C1-3 haloalkil, cijano-C1-3 alkil, HO-C1-3 alkil, CF3-C1-3 hidroksialkil, C1-3 alkoksi-C1-3 alkil, C3-7 cikloalkil, C1-3 alkoksi, C1-3 haloalkoksi, H2N-, (C1-3 alkil)NH-, (C1-3 alkil)2N-, HS-, C1-3 alkil-S-, C1-3 alkil-S(=O)-, C1-3 alkil-S(=O)2-, karbamil, C1-3 alkilkarbamil, di(C1-3 alkil)karbamil, karboksi, C1-3 alkil-C(=O)-, C1-4 alkoksi-C(=O)-, C1-3 alki-C(=O)O-, C1-3 alkil-C(=O)NH-, C1-3 alkil-S(=O)2NH-, H2N-SO2-, C1-3 alkil-NH-S(=O)2-, (C1-3 alkil)2N-S(=O)2-, H2N-S(=O)2NH-, C1-3 alkil-NHS(=O)2NH-, (C1-3 alkil)2N-S(=O)2NH-, H2N-C(=O)NH-, C1-3 alkil-NHC(=O)NH- i (C1-3 alkil)2N-C(=O)NH-.
4. Spoj prema zahtjevu 3, ili njegova farmaceutski prihvatljiva sol, naznačen time da:
R1 je C1-6 alkil, C1-6 haloalkil, C3-6 cikloalkil, ili C3-6 cikloalkil-C1-3 alkil, pri čemu je svaki navedeni C1-6 alkil, C3-6 cikloalkil i C3-6 cikloalkil-C1-3 alkil, proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se neovisno biraju između fluoro,
-CF3 i metil;
R2 je H ili metil;
R3 je H, F, ili Cl;
R4 je H ili F;
R5 je H ili F;
R6 je H ili F;
R7 je H, metil, etil ili HO-CH2-;
R8 je H ili metil;
R9 je H, metil ili etil; i
R10 je H, metil, etil ili HO-CH2-.
5. Spoj prema bilo kojem od zahtjeva 2 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time da:
a) Y je N; ili
b) Y je CH.
6. Spoj prema bilo kojem od zahtjeva 2 do 5, ili njegova farmaceutski prihvatljiva sol, naznačen time da:
a) X je N; ili
b) X je CR4; ili
c) X je CR4, i R4 je H ili F.
7. Spoj prema bilo kojem od zahtjeva 2 do 6, ili njegova farmaceutski prihvatljiva sol, naznačen time da:
a) W je N; ili
b) W je CR6; ili
c) W je CR6, i R6 je H, F, ili Cl; ili
d) W je CR6, i R6 je H ili F; ili
e) W je CR6, i R6 je H.
8. Spoj prema bilo kojem od zahtjeva 2 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time da R3 predstavlja H ili F.
9. Spoj prema bilo kojem od zahtjeva 2 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen time da R5 predstavlja H ili F.
10. Spoj prema bilo kojem od zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, naznačen time da:
a) R2 je H ili metil; ili
b) R2 je H.
11. Spoj prema bilo kojem od zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen time da:
a) R1 je C1-6 alkil, C1-6 haloalkil, C3-6 cikloalkil, ili C3-6 cikloalkil-C1-3 alkil, pri čemu je svaki od navedenih C1-6 alkil, C3-6 cikloalkil i C3-6 cikloalkil-C1-3 alkil, proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se neovisno biraju između fluoro, -CF3 i metil; ili
b) R1 je izopropil, etil, 1-metilpropil, 2,2,2-trifluoro-1-metiletil, 1-ciklopropiletil, ciklopropil, 1-trifluorometilciklopropil, 1-ciklopropil-2,2,2-trifluoroetil, 2,2,2-trifluoroetil, ili 2,2-difluoroetil; ili
c) R1 je izopropil, etil, 1-metilpropil, ili 2,2,2-trifluoro-1-metiletil.
12. Spoj prema bilo kojem od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time da R7 predstavlja H, metil, etil, ili HO-CH2-.
13. Spoj prema bilo kojem od zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, naznačen time da
a) R8 je H ili metil; ili
b) R8 je H.
14. Spoj prema bilo kojem od zahtjeva 1 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time da
a) R9 je H, metil ili etil; ili
b) R9 je H; ili
c) R9 je metil.
15. Spoj prema bilo kojem od zahtjeva 1 do 14, ili njegova farmaceutski prihvatljiva sol, naznačen time da
a) R10 je H, metil, etil, ili HO-CH2-; ili
b) R10 je H; ili
c) R10 je metil; ili
d) R10 is etil; ili
e) R10 je HO-CH2-.
16. Spoj prema bilo kojem od zahtjeva 1-4 i 6-15, ili njegova farmaceutski prihvatljiva sol, naznačen time da
a) ima Formulu II:
[image]
ili njegova farmaceutski prihvatljiva sol; ili
b) ima formulu III:
[image]
ili njegova farmaceutski prihvatljiva sol; ili
c) ima formulu IV:
[image]
ili njegova farmaceutski prihvatljiva sol; ili
d) ima formulu IIa:
[image]
ili njegova farmaceutski prihvatljiva sol; ili
e) ima formulu IIIa:
[image]
ili njegova farmaceutski prihvatljiva sol; ili
f) ima formulu IVa:
[image]
ili njegova farmaceutski prihvatljiva sol.
17. Spoj prema zahtjevu 1, naznačen time da da je odabran iz skupne koja sadrži:
5-[3-(cijanometil)-3-(3’-metil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-N-[(1S)-2,2,2-trifluoro-1-metiletil]pirazin-2-karboksamid;
5-[3-(cijanometil)-3-(3’-metil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-N-izopropilpirazin-2-karboksamid;
4-[3-(cijanometil)-3-(3’-metil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-N-
izopropilbenzamid;
4-[3-(cijanometil)-3-(3’-metil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamid;
4-[3-(1H,1’H-4,4’-bipirazol-1-il)-3-(cijanometil)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamid;
5-[3-(cijanometil)-3-(3,3’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-N-
izopropilpirazin-2-karboksamid;
4-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamid;
5-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-N-
izopropilpirazin-2-karboksamid;
5-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-N-[(1S)-2,2,2-trifluoro-1-metiletil]pirazin-2-karboksamid;
5-[3-(cijanometil)-3-(3-metil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-N-izopropilpirazin-2-karboksamid;
5-[3-(cijanometil)-3-(3’-etil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-N-[(1S)-2,2,2-
trifluoro-1-metiletil]pirazin-2-karboksamid;
4-{3-(cijanometil)-3-[3’-(hidroksimetil)-1H,1’H-4,4’-bipirazol-1-il]azetidin-1-il}-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamid;
4-{3-(cijanometil)-3-[3-(hidroksimetil)-3’-metil-1H,1’H-4,4’-bipirazol-1-il]azetidin-1-il}-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamid;
ili njegova farmaceutski prihvatljiva sol.
18. Spoj prema zahtjevu 1, naznačen time da predstavlja 4-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamid, ili njegova farmaceutski prihvatljiva sol.
19. Sol prema zahtjevu 1, naznačena time da se bira iz skupa koji sadži:
4-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamidnu sol fosforne kiseline;
4-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamidnu sol klorovodične kiseline;
4-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamidnu sol bromovodične kiseline; i
4-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamidnu sol sumporne kiseline.
20. Pripravak, naznačen time da sadrži spoj ili sol prema bilo kojem od zahtjeva 1 do 19, te farmaceutski prihvatljiv nosač.
21. Postupak inhibiranja aktivnosti JAK1, naznačen time da se sastoji od:
a) dovođenja in vitro u kontakt JAK1 sa spojem ili soli prema bilo kojem od zahtjeva 1 do 19; ili
b) dovođenja in vitro u kontakt JAK1 sa spojem ili soli prema bilo kojem od zahtjeva 1 do 19, pri čemu su navedeni spoj ili sol selektivni za JAK1, u usporedbi s JAK2.
22. Spoj ili sol prema bilo kojem od zahtjeva 1 do 19 naznačen time da je za upotrebu, u postupku za liječenje autoimune bolesti, raka, mijeloproliferativnog poremećaja, upalne bolesti, bolesti resorpcije kosti ili odbacivanja transplantiranog organa.
23. Spoj ili sol za upotrebu prema zahtjevu 22, naznačen time da
a) navedena autoimuna bolest predstavlja poremećaj na koži, multiplu sklerozu, reumatoidni artritis, psorijazni artritis, juvenilni artritis, dijabetes tip I, lupus, upalnu bolest crijeva, Crohnovu bolest, mijasteniju gravis, imunoglobulinsku nefropatiju, miokarditis, ili autoimuni poremećaj štitnjače; ili
b) navedena autoimuna bolest predstavlja reumatoidni artritis; ili
c) navedena autoimuna bolest predstavlja poremećaj na koži; ili
d) navedena autoimuna bolest predstavlja poremećaj na koži, pri čemu navedeni poremećaj na koži predstavlja atopijski dermatitis, psorijazu, senzibilizaciju kože, iritaciju kože, crvenilo kože, kontaktni dermatitis ili allergijsku kontaktnu senzibilizaciju.
24. Spoj ili sol za upotrebu prema zahtjevu 22, naznačen time da
a) navedeni rak predstavlja solidni tumor; ili
b) navedeni rak predstavlja rak prostate, rak bubrega, rak jetre, rak dojke, rak pluća, rak štitnjače, Kaposijev sarkom, Castlemanovu bolest ili rak gušterače; ili
c) navedeni rak predstavlja limfom, leukemiju, ili multipli mijelom.
25. Spoj ili sol za upotrebu prema zahtjevu 22, naznačen time da
a) navedeni mijeloproliferativni poremećaj predstavlja policitemija vera (PV), primarna trombocitemija (ET), primarna mijelofibroza (PMF), kronična mijelogena leukemija (CML), kronična mijelomonocitna leukemija (CMML), hipereozinofilni sindrom (HES), idiopatska mijelofibroza (IMF) ili sistemska bolest mastocitnih stanica (SMCD); ili
b) navedeni mijeloproliferativni poremećaj predstavlja mijelofibroza; ili
c) navedeni mijeloproliferativni poremećaj predstavlja primarna mijelofibroza (PMF); ili
d) navedeni mijeloproliferativni poremećaj predstavlja post policitemija vera mijelofibroza (Post-PV MF); ili
e) navedeni mijeloproliferativni poremećaj predstavlja post-esencijalna trombocitemija mijelofibroza (Post-ET MF).
26. Spoj ili sol za upotrebu prema bilo kojem od zahtjeva 1 do 19 naznačen time da je za postupak liječenja:
a) mijelodisplastičnog sindroma (MDS); ili
b) mijelodisplastičnog sindroma (MDS), pri čemu se navedeni mijelodisplastični sindrom bira od refraktorne citopenije s displazijom jedne loze (RCUD), refraktorne anemije s prstenastim sideroblastima (RARS), refraktorne citopenije s displazijom više loza, refraktorne anemije sa suviškom blasta-1 (RAEB-1), refraktorne anemije sa suviškom blasta-2 (RAEB-2), mijelodisplatičnog sindroma, neklasificiranog (MDS-U) i mijelodisplatičnog sindroma povezanog s izoliranim del(5q).
27. Postupak za pripremanje 4-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamidne soli fosforne kiseline, naznačen time da se sastoji od:
(a) otapanja 4-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamidne soli fosforne kiseline u metanolu, na temperaturi od 40°C do 70°C, uz nastanak primarne smjese;
(b) dodavanja n-heptana ovoj primarnoj smjesi, na temperaturi od 40°C do 70°C, uz nastanak sekundarne smjese; i
(c) hlađenja navedene sekundarne smjese, tako da se dobije 4-[3-(cijanometil)-3-(3’,5’-dimetil-1H,1’H-4,4’-bipirazol-1-il)azetidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benzamidnu sol fosforne kiseline.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361824683P | 2013-05-17 | 2013-05-17 | |
PCT/US2014/038388 WO2014186706A1 (en) | 2013-05-17 | 2014-05-16 | Bipyrazole derivatives as jak inhibitors |
EP14732705.0A EP2997023B9 (en) | 2013-05-17 | 2014-05-16 | Bipyrazole derivatives as jak inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170795T1 true HRP20170795T1 (hr) | 2017-08-25 |
Family
ID=50983151
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231048TT HRP20231048T1 (hr) | 2013-05-17 | 2014-05-16 | Derivati bipirazola kao jak inhibitori |
HRP20170795TT HRP20170795T1 (hr) | 2013-05-17 | 2017-05-29 | Derivati bipirazola kao inhibitori jak |
HRP20190713TT HRP20190713T1 (hr) | 2013-05-17 | 2019-04-16 | Sol bipirazola kao jak inhibitor |
HRP20210119TT HRP20210119T1 (hr) | 2013-05-17 | 2021-01-22 | Derivati bipirazola kao jak inhibitori |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231048TT HRP20231048T1 (hr) | 2013-05-17 | 2014-05-16 | Derivati bipirazola kao jak inhibitori |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20190713TT HRP20190713T1 (hr) | 2013-05-17 | 2019-04-16 | Sol bipirazola kao jak inhibitor |
HRP20210119TT HRP20210119T1 (hr) | 2013-05-17 | 2021-01-22 | Derivati bipirazola kao jak inhibitori |
Country Status (35)
Country | Link |
---|---|
US (6) | US9382231B2 (hr) |
EP (5) | EP3527263B1 (hr) |
JP (4) | JP6415543B2 (hr) |
KR (3) | KR102442747B1 (hr) |
CN (2) | CN105452239B (hr) |
AR (2) | AR096330A1 (hr) |
AU (5) | AU2014265279B2 (hr) |
BR (1) | BR112015028501B8 (hr) |
CA (1) | CA2911536C (hr) |
CL (1) | CL2015003355A1 (hr) |
CR (2) | CR20190156A (hr) |
CY (3) | CY1119105T1 (hr) |
DK (3) | DK3527263T3 (hr) |
EA (2) | EA039660B1 (hr) |
ES (4) | ES2626793T3 (hr) |
FI (1) | FI3786162T3 (hr) |
HK (2) | HK1221466A1 (hr) |
HR (4) | HRP20231048T1 (hr) |
HU (4) | HUE063817T2 (hr) |
IL (4) | IL242453B (hr) |
LT (4) | LT3786162T (hr) |
ME (2) | ME02763B (hr) |
MX (2) | MX2020004506A (hr) |
MY (1) | MY174788A (hr) |
PE (2) | PE20160126A1 (hr) |
PH (2) | PH12015502563B1 (hr) |
PL (4) | PL3786162T3 (hr) |
PT (4) | PT3231801T (hr) |
RS (4) | RS58743B1 (hr) |
SG (2) | SG10201709469SA (hr) |
SI (4) | SI3231801T1 (hr) |
TR (1) | TR201905814T4 (hr) |
TW (2) | TWI719401B (hr) |
UA (1) | UA117830C2 (hr) |
WO (1) | WO2014186706A1 (hr) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2348023B9 (en) | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
CN102458581B (zh) | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 |
ME01838B (me) | 2009-06-29 | 2014-12-20 | Lncyte Holdings Corp | Pirimidinoni kao inhibitori pi3k |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
KR102303885B1 (ko) | 2010-05-21 | 2021-09-24 | 인사이트 홀딩스 코포레이션 | Jak 저해제에 대한 국소 제형 |
EP2640723A1 (en) | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
MX2020004502A (es) | 2011-09-02 | 2022-01-20 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k). |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
PE20151141A1 (es) | 2012-11-01 | 2015-08-06 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
EA201590930A1 (ru) | 2012-11-15 | 2015-08-31 | Инсайт Корпорейшн | Лекарственные формы руксолитиниба с замедленным высвобождением |
JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤の製造方法及びその中間体 |
ME02763B (me) | 2013-05-17 | 2018-01-20 | Incyte Corp | Derivati bipirazola kao inhibitori jak |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
SI3110409T1 (sl) * | 2014-02-28 | 2018-11-30 | Incyte Corporation | Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov |
KR20230044320A (ko) | 2014-04-08 | 2023-04-03 | 인사이트 코포레이션 | Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료 |
SG10201809518QA (en) | 2014-04-30 | 2018-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
WO2015184305A1 (en) * | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
CR20170389A (es) | 2015-02-27 | 2018-01-26 | Incyte Corp | Sales de inhibidor de p13k y procesos de preparación |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
JP2018521000A (ja) * | 2015-05-29 | 2018-08-02 | シドネキシス,インク. | D2oで安定化された医薬製剤 |
MD3371190T2 (ro) | 2015-11-06 | 2022-09-30 | Incyte Corp | Compuși heterociclici ca inhibitori PI3K-gamma |
EP3400221B1 (en) | 2016-01-05 | 2020-08-26 | Incyte Corporation | Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors |
AR108875A1 (es) | 2016-06-24 | 2018-10-03 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
CN107759623B (zh) * | 2016-08-23 | 2020-08-14 | 苏州旺山旺水生物医药有限公司 | Jak抑制剂的中间体及其制备方法 |
AU2017324281A1 (en) * | 2016-09-06 | 2019-03-21 | F. Hoffmann-La Roche Ag | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof |
PE20210169A1 (es) | 2017-10-18 | 2021-01-29 | Incyte Corp | Derivados de imidazol condensados sustituidos por grupos de hidroxia terciaria como inhibidores de pi3k-y gamma |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CR20200379A (es) | 2018-01-30 | 2021-03-05 | Incyte Corp | Procesos e intermedio para elaborar un inhibidor de jak campo técnico |
KR20200128043A (ko) | 2018-02-16 | 2020-11-11 | 인사이트 코포레이션 | 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제 |
MA52655A (fr) | 2018-03-30 | 2021-02-17 | Incyte Corp | Biomarqueurs pour maladie cutanée inflammatoire |
CA3095487A1 (en) * | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
WO2019200030A1 (en) | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
CN108484468A (zh) * | 2018-05-11 | 2018-09-04 | 南京大学 | 芳基氮杂环丁烷类化合物的制备方法 |
DK3847175T3 (da) | 2018-09-05 | 2024-03-18 | Incyte Corp | Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor |
MX2021004946A (es) | 2018-10-31 | 2021-07-15 | Incyte Corp | Terapia combinada para tratamiento de enfermedades hematológicas. |
CN113692278A (zh) | 2018-12-19 | 2021-11-23 | 因赛特公司 | 用于治疗胃肠道疾病的jak1途径抑制剂 |
SG11202109563WA (en) | 2019-03-05 | 2021-09-29 | Incyte Corp | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20210123931A1 (en) | 2019-10-10 | 2021-04-29 | Incyte Corporation | Biomarkers for graft-versus-host disease |
CA3157499A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
JP2023506118A (ja) * | 2019-10-16 | 2023-02-15 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用 |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4157831A1 (en) | 2020-06-02 | 2023-04-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
KR20230096973A (ko) | 2020-08-18 | 2023-06-30 | 인사이트 코포레이션 | Jak 저해제를 제조하기 위한 방법 및 중간체 |
PE20231308A1 (es) | 2020-08-18 | 2023-08-24 | Incyte Corp | Proceso e intermedios para preparar un inhibidor de jak1 |
CN112159394B (zh) * | 2020-10-09 | 2021-10-22 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的小分子化合物及其用途 |
TW202237125A (zh) | 2020-12-04 | 2022-10-01 | 美商英塞特公司 | 用於治療皮膚疾病之jak抑制劑與維生素d類似物 |
CA3204374A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
CN112933095A (zh) * | 2020-12-29 | 2021-06-11 | 上海岸阔医药科技有限公司 | 预防或治疗egfr功能异常相关的副作用的方法 |
KR20230157307A (ko) | 2021-01-11 | 2023-11-16 | 인사이트 코포레이션 | Jak 경로 억제제 및 rock 억제제를 포함하는 병용 요법 |
JP2024516302A (ja) | 2021-05-03 | 2024-04-12 | インサイト・コーポレイション | 結節性痒疹を治療するためのjak1経路阻害薬 |
WO2024030600A1 (en) | 2022-08-05 | 2024-02-08 | Incyte Corporation | Treatment of urticaria using jak inhibitors |
CN117186078A (zh) * | 2023-11-06 | 2023-12-08 | 药康众拓(北京)医药科技有限公司 | 氘代氮杂环丁烷类jak抑制剂药物及用途 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5646749A (en) * | 1979-09-26 | 1981-04-28 | Mitsui Toatsu Chemicals | Protective sheet for surface |
JPS60106847U (ja) | 1983-12-27 | 1985-07-20 | 富士重工業株式会社 | 室外後写鏡 |
JP2650681B2 (ja) | 1987-07-10 | 1997-09-03 | 株式会社ブリヂストン | 空気ばね |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
CN1152031C (zh) | 1998-08-11 | 2004-06-02 | 诺瓦提斯公司 | 具有血管生成抑制活性的异喹啉衍生物 |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
CA2462657C (en) | 2001-10-30 | 2011-04-26 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
CN101106983A (zh) | 2004-11-24 | 2008-01-16 | 诺瓦提斯公司 | JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合 |
EP2348023B9 (en) | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
EP2220068B1 (en) * | 2007-11-16 | 2016-01-27 | Incyte Holdings Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
UA101493C2 (ru) * | 2008-03-11 | 2013-04-10 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
CN102458581B (zh) * | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
KR20180126619A (ko) | 2009-10-09 | 2018-11-27 | 인사이트 홀딩스 코포레이션 | 3-(4-(7H-피롤로〔2,3-d〕피리미딘-4-일)-1H-피라졸-1-일)-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체 |
BR112012020693B1 (pt) | 2010-02-18 | 2020-05-12 | Incyte Holdings Corporation | Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende |
ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
JP2013523884A (ja) * | 2010-04-14 | 2013-06-17 | アレイ バイオファーマ、インコーポレイテッド | JAKキナーゼの阻害剤としての5,7置換イミダゾ[1,2−c]ピリミジン |
KR102303885B1 (ko) | 2010-05-21 | 2021-09-24 | 인사이트 홀딩스 코포레이션 | Jak 저해제에 대한 국소 제형 |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EP2640723A1 (en) * | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
US8828987B2 (en) * | 2010-12-10 | 2014-09-09 | Rottapharm Biotech S.R.L. | Pyridine amide derivatives as EP4 receptor antagonists |
US9926601B2 (en) | 2011-02-24 | 2018-03-27 | Massachusetts Institute Of Technology | Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer |
US8691807B2 (en) * | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
AU2012312305B2 (en) | 2011-09-22 | 2016-11-17 | Merck Sharp & Dohme Corp. | Acyclic cyanoethylpyrazoles as janus kinase inhibitors |
TW201406761A (zh) * | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
PE20151141A1 (es) | 2012-11-01 | 2015-08-06 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
EA201590930A1 (ru) | 2012-11-15 | 2015-08-31 | Инсайт Корпорейшн | Лекарственные формы руксолитиниба с замедленным высвобождением |
JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤の製造方法及びその中間体 |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
AU2014267198A1 (en) | 2013-05-17 | 2015-11-05 | F. Hoffmann-La Roche Ag | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
ME02763B (me) | 2013-05-17 | 2018-01-20 | Incyte Corp | Derivati bipirazola kao inhibitori jak |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
SI3110409T1 (sl) | 2014-02-28 | 2018-11-30 | Incyte Corporation | Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov |
SG10201809518QA (en) | 2014-04-30 | 2018-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
AU2015365455B2 (en) | 2014-12-16 | 2019-01-17 | Novartis Ag | Isoxazole hydroxamic acid compounds as LpxC inhibitors |
EP4157831A1 (en) | 2020-06-02 | 2023-04-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor |
TW202237125A (zh) | 2020-12-04 | 2022-10-01 | 美商英塞特公司 | 用於治療皮膚疾病之jak抑制劑與維生素d類似物 |
-
2014
- 2014-05-16 ME MEP-2017-116A patent/ME02763B/me unknown
- 2014-05-16 LT LTEP20201593.9T patent/LT3786162T/lt unknown
- 2014-05-16 UA UAA201512465A patent/UA117830C2/uk unknown
- 2014-05-16 HU HUE20201593A patent/HUE063817T2/hu unknown
- 2014-05-16 BR BR112015028501A patent/BR112015028501B8/pt active IP Right Grant
- 2014-05-16 PL PL20201593.9T patent/PL3786162T3/pl unknown
- 2014-05-16 HU HUE17158350A patent/HUE043573T2/hu unknown
- 2014-05-16 KR KR1020217030190A patent/KR102442747B1/ko active IP Right Grant
- 2014-05-16 DK DK18215671.1T patent/DK3527263T3/da active
- 2014-05-16 EP EP18215671.1A patent/EP3527263B1/en active Active
- 2014-05-16 ME MEP-2019-79A patent/ME03355B/me unknown
- 2014-05-16 ES ES14732705.0T patent/ES2626793T3/es active Active
- 2014-05-16 WO PCT/US2014/038388 patent/WO2014186706A1/en active Application Filing
- 2014-05-16 RS RS20190315A patent/RS58743B1/sr unknown
- 2014-05-16 PT PT17158350T patent/PT3231801T/pt unknown
- 2014-05-16 PT PT147327050T patent/PT2997023T/pt unknown
- 2014-05-16 PL PL14732705T patent/PL2997023T3/pl unknown
- 2014-05-16 EP EP20201593.9A patent/EP3786162B1/en active Active
- 2014-05-16 LT LTEP17158350.3T patent/LT3231801T/lt unknown
- 2014-05-16 LT LTEP14732705.0T patent/LT2997023T/lt unknown
- 2014-05-16 ES ES18215671T patent/ES2845210T3/es active Active
- 2014-05-16 HR HRP20231048TT patent/HRP20231048T1/hr unknown
- 2014-05-16 SG SG10201709469SA patent/SG10201709469SA/en unknown
- 2014-05-16 CN CN201480032106.8A patent/CN105452239B/zh active Active
- 2014-05-16 MY MYPI2015002767A patent/MY174788A/en unknown
- 2014-05-16 US US14/279,929 patent/US9382231B2/en active Active
- 2014-05-16 SI SI201431118T patent/SI3231801T1/sl unknown
- 2014-05-16 AU AU2014265279A patent/AU2014265279B2/en active Active
- 2014-05-16 LT LTEP18215671.1T patent/LT3527263T/lt unknown
- 2014-05-16 MX MX2020004506A patent/MX2020004506A/es unknown
- 2014-05-16 RS RS20210074A patent/RS61482B1/sr unknown
- 2014-05-16 TW TW108103947A patent/TWI719401B/zh active
- 2014-05-16 PE PE2015002406A patent/PE20160126A1/es unknown
- 2014-05-16 ES ES20201593T patent/ES2960731T3/es active Active
- 2014-05-16 CA CA2911536A patent/CA2911536C/en active Active
- 2014-05-16 SI SI201430239A patent/SI2997023T1/sl unknown
- 2014-05-16 SI SI201431754T patent/SI3527263T1/sl unknown
- 2014-05-16 AR ARP140101971A patent/AR096330A1/es active IP Right Grant
- 2014-05-16 PT PT182156711T patent/PT3527263T/pt unknown
- 2014-05-16 DK DK20201593.9T patent/DK3786162T3/da active
- 2014-05-16 PE PE2020000001A patent/PE20200527A1/es unknown
- 2014-05-16 EP EP14732705.0A patent/EP2997023B9/en active Active
- 2014-05-16 MX MX2015015738A patent/MX2015015738A/es active IP Right Grant
- 2014-05-16 PL PL17158350T patent/PL3231801T3/pl unknown
- 2014-05-16 EA EA202090291A patent/EA039660B1/ru unknown
- 2014-05-16 PT PT202015939T patent/PT3786162T/pt unknown
- 2014-05-16 RS RS20230782A patent/RS64591B1/sr unknown
- 2014-05-16 SG SG11201509180WA patent/SG11201509180WA/en unknown
- 2014-05-16 TW TW103117400A patent/TWI664176B/zh active
- 2014-05-16 DK DK17158350.3T patent/DK3231801T3/en active
- 2014-05-16 FI FIEP20201593.9T patent/FI3786162T3/fi active
- 2014-05-16 KR KR1020157035750A patent/KR102341908B1/ko active IP Right Grant
- 2014-05-16 SI SI201432046T patent/SI3786162T1/sl unknown
- 2014-05-16 RS RS20170526A patent/RS56012B1/sr unknown
- 2014-05-16 EP EP23185889.5A patent/EP4275756A3/en active Pending
- 2014-05-16 HU HUE18215671A patent/HUE053122T2/hu unknown
- 2014-05-16 TR TR2019/05814T patent/TR201905814T4/tr unknown
- 2014-05-16 ES ES17158350T patent/ES2720073T3/es active Active
- 2014-05-16 HU HUE14732705A patent/HUE033587T2/hu unknown
- 2014-05-16 PL PL18215671T patent/PL3527263T3/pl unknown
- 2014-05-16 EA EA201592199A patent/EA036448B1/ru unknown
- 2014-05-16 CR CR20190156A patent/CR20190156A/es unknown
- 2014-05-16 CN CN201711000293.3A patent/CN107698569B/zh active Active
- 2014-05-16 KR KR1020227030853A patent/KR20220127371A/ko active IP Right Grant
- 2014-05-16 JP JP2016514126A patent/JP6415543B2/ja active Active
- 2014-05-16 EP EP17158350.3A patent/EP3231801B1/en active Active
-
2015
- 2015-11-04 IL IL24245315A patent/IL242453B/en active IP Right Grant
- 2015-11-12 PH PH12015502563A patent/PH12015502563B1/en unknown
- 2015-11-13 CL CL2015003355A patent/CL2015003355A1/es unknown
- 2015-12-03 CR CR20150633A patent/CR20150633A/es unknown
-
2016
- 2016-06-20 US US15/187,296 patent/US9926301B2/en active Active
- 2016-08-11 HK HK16109588.1A patent/HK1221466A1/zh unknown
-
2017
- 2017-05-29 HR HRP20170795TT patent/HRP20170795T1/hr unknown
- 2017-06-08 CY CY20171100610T patent/CY1119105T1/el unknown
-
2018
- 2018-02-15 US US15/897,598 patent/US10435392B2/en active Active
- 2018-04-18 HK HK18105021.2A patent/HK1245769B/zh unknown
- 2018-08-31 AU AU2018223058A patent/AU2018223058B2/en active Active
- 2018-10-02 JP JP2018187613A patent/JP6775560B2/ja active Active
- 2018-10-02 PH PH12018502125A patent/PH12018502125A1/en unknown
-
2019
- 2019-01-22 IL IL264409A patent/IL264409B/en active IP Right Grant
- 2019-04-16 HR HRP20190713TT patent/HRP20190713T1/hr unknown
- 2019-05-10 CY CY20191100510T patent/CY1121763T1/el unknown
- 2019-08-29 US US16/555,620 patent/US11001571B2/en active Active
-
2020
- 2020-02-17 AR ARP200100433A patent/AR118120A2/es unknown
- 2020-03-19 AU AU2020202000A patent/AU2020202000B2/en active Active
- 2020-10-06 JP JP2020168950A patent/JP7126741B2/ja active Active
-
2021
- 2021-01-22 HR HRP20210119TT patent/HRP20210119T1/hr unknown
- 2021-01-22 CY CY20211100050T patent/CY1123756T1/el unknown
- 2021-04-13 US US17/229,397 patent/US11591318B2/en active Active
- 2021-04-26 IL IL282644A patent/IL282644B/en unknown
- 2021-04-29 AU AU2021202685A patent/AU2021202685B2/en active Active
- 2021-10-17 IL IL287313A patent/IL287313B/en unknown
-
2022
- 2022-08-10 JP JP2022128042A patent/JP2022163162A/ja active Pending
- 2022-10-31 AU AU2022263454A patent/AU2022263454B2/en active Active
-
2023
- 2023-01-24 US US18/101,014 patent/US11905275B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170795T1 (hr) | Derivati bipirazola kao inhibitori jak | |
JP2016519147A5 (hr) | ||
HRP20170456T1 (hr) | Novi kondenzirani derivati pirimidina, namijenjeni inhibiranju aktivnosti tirozinske kinaze | |
ES2879474T3 (es) | Compuestos y composiciones para modular las actividades de la quinasa mutante de EGFR | |
HRP20140437T1 (hr) | Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora | |
HRP20230458T1 (hr) | Piridazinoni kao inhibitori parp7 | |
HRP20171913T1 (hr) | Aminopirimidinilni spojevi kao inhibitori jak | |
HRP20170017T1 (hr) | Inhibitori tirozin kinaze | |
HRP20130106T1 (hr) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
HRP20180546T1 (hr) | Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti | |
JP2014520146A5 (hr) | ||
RU2015156142A (ru) | Бисульфат ингибитора янус-киназы (jak) и способ его получения | |
JP2018532737A5 (hr) | ||
HRP20170119T1 (hr) | Novi derivati pirimidina, njihovo pripremanje, te njihova farmaceutska uporaba kao inhibitora akt (pkb) fosforilacije | |
HRP20150858T1 (hr) | Inhibitori bromodomena i njihove uporabe | |
RU2011125376A (ru) | Способ получения соединений дигидроинденамида, фармацевтические композиции, содержащие данные соединения, и их применение в качестве ингибитора протеинкиназы | |
RU2009127095A (ru) | Новые оксадиазольные соединения | |
JP2023105214A (ja) | Btk阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法 | |
AR078833A1 (es) | Derivados de heteroarilos que contienen nitrogeno como inhibidores dela cinasa jak3 | |
RU2009125916A (ru) | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения | |
RU2014121073A (ru) | Бициклические соединения пиперазина | |
RU2014131378A (ru) | Ингибиторы бромдомена | |
EP2887943A1 (en) | Novel 4,6-disubstituted aminopyrimidine derivatives | |
RU2019104092A (ru) | Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака | |
PE20060582A1 (es) | Analogos de anilino-pirimidina |